Bristol-Myers Signs Deal with Sequitir for Antisense Compounds | GenomeWeb

NEW YORK, Jan 29 – Sequitir said Monday it signed a multi-year, multi-million dollar deal to supply Bristol-Myers Squibb with its antisense compounds for target validation and to perform biological screening for the pharmaceutical company.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.